Evotec AG
FY 2007 Results Presentation, March 28, 2008



Forward-looking statements

Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of our products, the consummation of our merger with Renovis, the timing of the completion of the merger, the anticipated benefits of the merger, including future financial and operating results, our post-merger plans, objectives, expectations and intentions, the anticipated timing and results of the combined company's clinical and pre-clinical programs, and other statements that are not historical facts. We caution readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. These include risks and uncertainties relating to: our ability to obtain regulatory approvals of the merger on the proposed terms and schedule; our ability to complete the merger because conditions to the closing of the transaction may not be satisfied; our failure to successfully integrate the businesses; unexpected costs or liabilities resulting from the merger; the risk that synergies from the merger may not be fully realized or may take longer to realize than expected; disruption from the merger making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on our international operations. The list of risks above is not exhaustive. Our Registration Statement on Form F-4 filed with the Securities and Exchange Commission in connection with the proposed merger with Renovis contains additional factors that could impact our businesses and financial performance following the merger. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Additional Information

We have filed a Registration Statement on Form F-4 with the Securities and Exchange Commission in connection with the proposed merger. Evotec and Renovis expect to mail a joint proxy statement/prospectus, which will form part of the Registration Statement on Form F-4, to shareholders of Renovis in connection with the proposed merger. This document will contain important information about the merger and should be read before any decision is made with respect to the merger. Investors and stockholders will be able to obtain free copies of this document and any other documents filed or furnished by Evotec or Renovis through the website maintained by the Securities and Exchange Commission at www.sec.gov. Free copies of these documents may also be obtained from Evotec, by directing a request to Evotec's Investor Relations department at Schnackenburgallee 114, 22525 Hamburg, Germany, or from Renovis, by directing a request to Renovis' Investor Relations department at Two Corporate Drive, South San Francisco, California 94080. You may also read and copy any reports, statements or other information filed or furnished by Evotec or Renovis at the SEC's Public Reference Room at Station Place, 100 F Street, N.E., Washington, D.C. 20549. You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference Room.

Agenda

01 Highlights 2007

02 Pipeline Update

03 Collaborations

04 FY 2007 Results

05 The Merger with Renovis

06 Outlook 2008

Highlights 2007

- Transition to a global biopharmaceutical company
  - Merger agreement signed with Renovis, shareholder approval expected May 01, 2008
  - Divestment of non-core assets for cash
- Clinical progress
  - EVT 201 preclinical and POC data suggest strong efficacy and safety profile
  - EVT 302 Phase I safety data: well tolerated up to the highest doses; Phase II craving study initiated in smoking cessation
- Liquidity position strengthened to pro-forma € 141 m
  - Strategic transactions led to a total increase of available funds of appr. € 83 m
  - Potential combination with Renovis further strengthens balance sheet
- Financial guidance for 2007 achieved

Financial guidance for 2007 achieved

Evotec Group (in €m)

	2006*	2007**	Δ	Guidance
Revenues	85	54	-36%	–
- Continuing business***	41	33	-19%	30 – 35
R&D expenses	33	37	+10%	–
Net income	(28)	(11)	+60%	–
Liquidity at year end	79	94	+19%	93 – 98

*** As restated**

**** Chemical Development Business (CPD) only 11 months**

***** 2006 excl. ET/CPD 2007 excl. CPD**

Strategic transformation



Strategic transformation



Strategic transformation

New Evotec



* Based on end of December 2007 cash, after expected transaction costs.

Agenda

01 Highlights 2007

02 Pipeline Update

03 Collaborations

04 FY 2007 Results

05 The Merger with Renovis

06 Outlook 2008

EVT 201: Strong Proof-of-Concept Data in 2007

Partial positive allosteric modulator for $GABA_A$ receptors

- Phase II results
  - Successfully completed in 2007
  - Data reviewed with members of a key opinion leader panel
  - Results offer great potential for a new treatment of insomnia
- Partnering
  - Data in discussion with potential partners
  - Co-development arrangements or further in-house differentiation studies to enhance value creation in partnering discussions also considered

Market need

- Datamonitor report on insomnia April 2007
- 5 areas of unmet need identified
  - 1: Reduction of residual daytime sedation
  - 2: More effective treatments for insomnia in the elderly
  - 3: Improvement in sleep maintenance
  - 4: Lack of potential for tolerance and addiction
  - 5: More effective treatments for pediatric insomnia
- EVT 201 has the potential to meet all of these unmet needs
  - Effect on Top 3 criteria already demonstrated
  - Expected to show less development of tolerance and addiction than existing treatments and has not yet been tested in paediatric patients

Our assessment of EVT 201's best-in-class profile: Expected differentiation on safety & efficacy

- Longer duration of action, more sustained effect in the 2nd half of the night
  - vs Ambien CR, continued dosing leads to tolerance
  - pPAM pharmacology expected to produce less tolerance; maintains duration of action
- Beneficial effects upon next day sleepiness
  - In elderly with daytime sleepiness due to insomnia, using gold standard methods
  - No similar data on Ambien CR, Lunesta published
- Potential for superior safety profile as a result of its pPAM pharmacology
  - Potentially better tolerated at therapeutic dose or multiples
    - Vs. full agonists at the $GABA_A$ receptor such as zolpidem

Best-in-class potential on safety & efficacy

Principle Investigator Dr James Walsh

Executive Director of the Sleep Medicine and Research Center, St John's Mercy Medical Center

"EVT 201 appears to have an ideal pharmacokinetic profile and dose relationship to promote sleep induction and sleep maintenance for 7-8 hours, without risk of daytime sedation.

In fact, in one study insomnia patients were objectively more alert throughout the day when treated for only one week.

Moreover, as a partial agonist of $GABA_A$ receptors EVT201 may result in fewer side effects than full agonists.

Thus, EVT201 may have a better efficacy-safety ratio (index) as compared to current treatments."

March 2008

EVT 302: Good safety data and start of Phase II

Selective MAO-B inhibitor for smoking cessation & Alzheimer's

- Multiple ascending dose study in healthy subjects successfully completed
  - Well tolerated in young & elderly up to the highest dose levels
  - No significant adverse events or concerns from all safety assessments incl liver function tests
  - Highly predictive pharmacokinetics with low variability
- Assessment on selective inhibition of MAO-B with lack of MAO-A inhibition in humans ongoing
- Phase II craving study progressing to plan
  - Single dose of EVT 302 alone / in combination with Nicotine Replacement Therapy
  - Results expected in Q3 2008

EVT 302: Single ascending and multiple dose PET study successfully completed

- Single ascending dose PET study in 18 healthy subjects dosed up to 15 mg
  - Dose dependent occupancy and complete blockade of MAO-B achieved in relevant areas of brain
  - Potency of EVT 302 higher than that of the comparator selegiline
  - Excellent correlation of brain MAO-B occupancy with plasma concentration of EVT 302
  - Results taken as basis for planning of a multiple dose PET study
- Multiple dose PET study in 18 healthy subjects
  - Full occupancy of MAO-B achieved in relevant areas of brain after the second day of dosing with EVT 302
  - Potential for weekly dosing feasible based on the PET results

Dose selected for Phase II quit rate study

EVT 302: Phase II proof-of-concept quit rate study to start in H2

Design in progress

- 8 weeks treatment in smokers withdrawing from cigarettes
  - 4 groups in parallel design – estimated patient number 400
  - EVT 302 once daily, placebo, with and without nicotine replacement therapy
- Commonly used endpoints
  - 4 week quit rate + 7 day prevalence quit rate
  - Responder rates
  - Markers of consumption and subjective assessments of craving and mood etc
- To be conducted in Germany
- Clinical phase of study commences mid 2008 – subject to usual approvals
  - Headline data H1 2009

EVT 101: 4 week Phase Ib higher repeat dose cognition study, dosing completed

- Study conducted in France and dosing has completed satisfactorily
  - No significant adverse events or concerns from all safety monitoring assessments
  - EVT 101 continues to be well tolerated
- Blinded results from lower of two dose levels available to date
  - Results of second dose levels available by end Q2 2008
- Cerebrospinal fluid (CSF) penetration assessed in a subgroup receiving EVT 101 daily for 8 days



EVT 101:
Brain imaging fMRI study in healthy volunteers completed

- Study completed at Institute of Psychiatry London
- Single dose of placebo, 8, 15 mg EVT 101 given to 19 healthy subjects
  - EVT 101 well tolerated with no significant adverse effects

- **Modulation of the activity of specific brain regions during the performance of cognitive tasks**
- **Increase in baseline regional blood flow in the anterior cingulate cortex**
- **Provides first evidence of effect upon brain in man**
- **Modulation of memory retrieval network encouraging for activity in Alzheimer's disease**
- **Anterior cingulate cortex is concerned with response to pain and is rich in NR2B receptors**
  - **Supports role in pain states**

Phase Ib fMRI study: EVT 101-induced changes in rCBF



EVT 101: Progress in response to FDA IND review

- Additional preclinical studies requested by FDA have been initiated
- Studies progressing to plan and expectations
- Start of single dose spinal cord injury associated neuropathic pain study in US dependent on these results and their review by FDA

EVT 101: Summary of progress

- Phase I
  - fMRI study completed and reported today; dosing in 4 week higher repeat dose study completed
  - At a dose level which was safe and well tolerated EVT 101 demonstrated penetration into the CSF to occupy NR2B receptors to a significantly higher level than memantine at its therapeutic dose in Alzheimer's Disease
  - Data from fMRI study demonstrates first data of effect upon CNS in man
  - At the same dose level changes in regional blood flow demonstrated in the human brain in an area important in pain response
- Phase II
  - Necessary additional preclinical work as requested by FDA in progress
  - Phase II study could start in 2008 in either Alzheimer's Disease or neuropathic pain

Progress on additional development programs

- EVT 103
  - Preclinical toxicology completed satisfactorily
  - Progression to Phase I planned – timing dependent on budget
- Renovis P2X7 antagonist
  - Preclinical toxicology completed satisfactorily
  - Planned first in human Phase I study mid 2008
- Renovis VR1 antagonist program
  - Phase I studies expected to begin mid 2008
  - Development costs are incurred by Pfizer

Agenda

01 Highlights 2007

02 Pipeline Update

03 Collaborations

04 FY 2007 Results

05 The Merger with Renovis

06 Outlook 2008

evotec

Research results for a top quality customer network

Almirall

Boehringer Ingelheim

Cardioxyl PHARMACEUTICALS

CHDI

DAIICHI PHARMACEUTICAL CO., LTD.

FERRING PHARMACEUTICALS

GENEXTRA

GRÜNENTHAL

InterMune

JT

Lilly

MERCK SERONO

NYCOMED

Panacos

Pfizer

RECORDATI

Roche

SOLACE

Solvay Pharmaceuticals

spermatech

TiGenix
DEFINING THE CUTTING EDGE IN REGENERATIVE MEDICINE

Vifor International

Strategic progress

- Higher value and strategic deals in preferred therapeutic areas
  - Boehringer Ingelheim collaboration extended for another year
  - Significant expansion of CHDI collaboration in Huntington‘s Disease
  - Expansion of DAC collaboration into medicinal chemistry phase
- Technical differentiation
  - Fragment-based drug discovery platform EVOlution™ successfully established
  - Deals signed with DAC, Intermune, Ono, others
  - Acquisition of Combinature to expand fragment-based platform

High-value added, results-based collaborations

- Deliver preclinical candidates exploiting Evotec's GPCR and other target class expertise
- 76 FTE committed (36 from Evotec)
- Duration 6 years
  - Extended in 2008 for another year
- Research payments, milestones, royalties, rights back

- CNS project on undisclosed target
- Screening of both compound libraries completed
- Both companies apply chemistry resources to the hits identified
- Joint research, option rights, milestones (potentially > €100m), royalties

Substantial contracts in preferred therapeutic areas

- Three-year extension of integrated drug discovery contract in Huntington‘s Disease
- Worth up to US $ 37m
- Covers Evotec’s entire drug discovery offering
- Example for strategic expertise in CNS

- Biology and medicinal chemistry support
- Continued into the second year of collaboration
- Different therapeutic areas

Fragment-based drug discovery platform EVOlution™ leads to significant new deal flow

- Collaboration on HSP90 advanced well into lead optimization based on fragment-based approach
- Validation phase completed generating novel IP

- Fragment-based drug discovery program yields positive results and leads to expansion of the collaboration
- Technology access fee to EVOlution™, plus ongoing research funding

- Three-year fragment-based drug discovery / medicinal chemistry agreement
- Technology access fee to EVOlution™, plus ongoing research funding and success payments

Agenda

01 Highlights 2007

02 Pipeline Update

03 Collaborations

04 FY 2007 Results

05 The Merger with Renovis

06 Outlook 2008

Key financials 2007: Increased R&D investment

Condensed Profit & Loss Statement (IFRS) – continuing business in €m

	2006 Actual	2007 Actual	% vs. Actual 06
Revenues	40.6	32.9	-19%
Gross margin	33.9%	24.4%	
– R&D expenses	30.3	36.9	+22%
– SG&A expenses	15.0	17.8	+18%
– Amortization & impairment	2.7	11.1	+318%
– Restructuring expenses	0.0	0.4	
– Other operating expenses	0.3	-0.1	-134%
Operating income (loss)	-34.5	-58.1	-68%
Net income (loss)	**-29.0**	**-48.1**	**-66%**
Net income (loss) discontinued operations	1.3	36.9	–
Net income (loss) total	**-27.7**	**-11.2**	**+60%**

Revenues impacted by library JV and absence of milestone payments in 2007

Revenues, continuing business (in €m)



Adjusted for foreign exchange ongoing business increased by 9%

Revenues, continuing business (in €m)



Milestone payments lead to margin volatility

Group gross margin, continuing business (in %)



Key drivers:

- Milestone impact:
  € 3.2m milestones improved GM in 2006 by 6%
- Currency effect due to weak USD : -3%-points
- Different revenue-mix towards higher risk milestone-earning projects

Research & Development (R&D): Creating pipeline value

Group R&D spend, continuing business (in €m)



2007:

- €36.9m for proprietary R&D
(Discovery: 23% / Clinical Development: 64%)

2006:

- €23.7m for proprietary R&D
(Discovery: 24% / Clinical Development: 57%)
- €6.6m spend for in-licensing of EVT 301/302

Higher operating loss mainly due to lower GP, increased R&D investment & impairment

Operating result, continuing business* (in €m)



Amortization & Impairment 2006

Amortization intangible assets	€ 3.3m
Reversal of impairment	€ -0.6m

Amortization & Impairment 2007

Amortization intangible assets	€ 2.6m
Impairment Goodwill OAI	€ 5.8m
Impairment int. assets ENS	€ 3.2m
Impairment int. assets Neuro3d	€ 0.1m
Reversal of impairment	€ -0.6m

*** 2006 as restated**

Net Income improved by 60%

Net loss, total business* (in €m)



Net income in 2007 improved by the divestment of

- ET €11.2m
- CPD € 25.2m

*** 2006 as restated**

Chemical Development Business, sold to Aptuit effective November 30, 2007 : Discontinued operations

Condensed Profit & Loss Statement (IFRS) – Chemical Development Business (CPD) in €m

	2006 Actual	2007 Actual*	% vs. Actual 06
Revenues	26.8	21.5	-20%
Gross margin	34.3%	25.5%	
– R&D expenses	0.0	0.0	
– SG&A expenses	3.8	3.1	-17%
– Impairment of Goodwill	6.6	0.0	
– Other operating expenses	1.3	0.0	
Operating income (loss)	-2.5	2.3	+194%
Operating income (loss) before Amortization & Impairment	**4.1**	**2.3**	**-43%**

*** CPD only 11 months**

Cash development (incl. investments) 2007*: Cash flow from operations dominated by R&D expenditure

in € m



* Continuing business

Sharpening the focus on proprietary research

Employees as of Dec 31, year-end, total business



Growing R&D discovery operations

Reduced asset base due to divestments

Balance sheet – Assets* (in €m)



*** 2006 as restated**

Capital expenditures handled restrictively, includes € 1.1m acquired assets from Combinature

Capital expenditures – continuing business * / ** (in €m)



*** Without finance leases**

**** 2006 as restated**

Equity ratio increased to 82%

Balance sheet – Liabilities & stockholders' equity* (in €m)



* 2006 as restated

Agenda

01 Highlights 2007

02 Pipeline Update

03 Collaborations

04 FY 2007 Results

05 The Merger with Renovis

06 Outlook 2008

Renovis history

- 2004 IPO: 3 clinical programs
  - Lead program in stroke, positive data in May, 2005
  - Wall Street “darling” until October 2006 with pivotal trial failure
  - Peak market cap: ~$700 million

- 2006 Re-start: Trading at cash, <$100 million
  - Down-sizing, top management departed
  - Focused, integrated preclinical small molecule discovery/development
  - Chemistry/biology expertise, proprietary drug-like libraries
  - 2 INDs are expected in 2008, including key Pfizer collaboration

The combination: Multi-faceted pipeline, strong fit and differentiating science



VR1 - Vanilloid Receptor 1 antagonist

Exclusive worldwide collaboration

- Pooled program signed Q2 2005
- >$20m+ lic. fees & research funding
- $170m+ milestones possible for each product candidate
  - $1.5m milestone payment (2006)
  - $4.5m milestone payment (2007)
- Double-digit royalties on w/w net sales
- Two-year joint research effort
  - Extended for additional year, April 2007
- Multiple clinical candidates
- Pfizer has exclusive rights to develop and commercialize products
  - Expect Phase I studies in mid 2008

VR1 - Vanilloid Receptor 1 antagonist

Potential for safe, best-in-class analgesic, non-addictive, minimal side effects

- Clinical & preclinical validation for pain
- Competitive R&D activity
- Potentially ideal drug profile…
  - Strong analgesic
  - Non-addictive
  - Minimal side effects
- Broadly applicable analgesic
  - Inflammatory, OA, & neuropathic pain
  - Chronic and acute pain
- … with potential in other indications
  - Urinary incontinence
  - Asthma and others



$P2X_7$ receptor antagonist

Potential best-in-class molecule

- Strong industry interest
  - Best-in-class opportunity
- Multiple large potential indications
  - Pain, RA, IBD, COPD
- Clinical candidate & back-up series
- Planned Phase 1 in 2008
- Partnering opportunity



$P2X_{2/3}$ receptor antagonist

- Validated for multiple pain types
- Strong industry interest: 1st-in-class
- Lead series with superior properties
- Multiple large potential indications
  - Inflammatory pain
  - Neuropathic pain
  - Urinary incontinence
- Planning Phase 1 in H1 2009



Key facts on Renovis acquisition

Data pro-forma

- Merger close
  - Form F-4 declared effective by the SEC in March 2008
  - NASDAQ listing expected in May 2008
  - Closing subject to shareholder vote on May 01, 2008
- 34.57m Evotec shares exchanged for 32.79m Renovis shares
  - Fixed share exchange rate of 1.0542 EVT for 1.0 RNVS
- Key data pro-forma (including Renovis)
  - Cash 31/12/2007: € 141m*
  - Cash run rate: 3 years
  - Headcount: approx. 440
  - # of shares: 108.8m
  - Market capitalization as of March 26, 2008: > US$ 280 m

* Based on end of December 2007 cash, after anticipated transaction costs.

Key anticipated benefits

- Operational footprint in leading biotech region – Bay Area in the US
  - Strong inflammation / pain talent pool
  - Academia
- Expansion / de-risking of pipeline
  - Several significant value inflection points in 2008/2009
- Pipeline funding
- NASDAQ liquidity

High-value and strategic partnerships: Milestones expected in 2008, 2009

Post-merger partnership profile

Boehringer Ingelheim	76 FTEs, 6 year collaboration, milestones, royalties
Pfizer	VR1, US$ 10m in upfront payment, >US$ 10m in FTE funding, >US$ 170m milestones, double-digit royalties
Roche	CNS target, milestones > €100 m, mid-single digit royalties
CHDI	Integrated drug discovery contracts in Huntington's Disease, worth up to US$ 37 m
ONO	3 year fragment-based drug discovery / medicinal chemistry agreement

Agenda

01 Highlights 2007

02 Pipeline Update

03 Collaborations

04 FY 2007 Results

05 The Merger with Renovis

06 Outlook 2008

Sales and Order Book

2008 Sales and Order Book, continuing business
Status as of February (in €m)



Financial guidance 2008 (incl. Renovis)

Revenues
before out-licensing income:
€34m - €36m

- Based on current order book, expected new contracts, contract extensions and some milestones
- May be substantially higher, depending on contribution from out-licensing and additional milestone income

R&D expenses
before employee stock compensation:
€46m - €51m

- Progress in clinical pipeline
  - Expected start of Phase II for EVT 302 & EVT 101
  - Advancing two drug candidates into the clinic
- Renovis acquisition

Liquidity Dec 31, 2008
excluding out-licensing payments:
> €85m

- Cash run at least 3 years - assumes no major out-licensing event

Our research plan 2008 (incl. Renovis)

	Budget 2008	Milestone
EVT 201	✓	Manufacturing/preclinical studies
EVT 101	✓	Completion Phase Ib studies / start of POC studies
EVT 302	✓	Start / completion of POC Phase II studies in Smoking Cessation
EVT 103	—	Subject to successful out-licensing of EVT 201 or others
VR1	✓	No R&D / funded by Pfizer
P2X7	✓	Start of Phase I studies
Discovery	✓	3-4 lead optimisation projects

Combined newsflow 2008

- NASDAQ listing (✓)
- Merger close
- EVT 101: - Ph Ib fMRI cognition data✓
  - Ph Ib higher repeat dose data
- EVT 302: - Ph I safety data ✓
  - Single / repeat dose PET data ✓
  - Initiate Ph II craving study ✓

- Partnership EVT 201
- EVT 302: - Initiate Ph II quit rate study
  - Ph II craving data
  - Tyramine interaction data
- EVT 101: Initiate Phase II POC
- VR1: Initiate Phase I
- P2X7: Initiate Phase I

H1 2008 H2 2008

Major value inflection points by end 2009

- Partnering opportunity for EVT 201 in 2008
- Phase II POC data for EVT 302 in 2008/2009
  - Craving study
  - Quit rate study
- Phase II POC data for EVT 101 in 2009
  - Depending on start and final study design
- Entry of several drug candidates into Phase I studies in 2008/2009

A compelling CNS investment

- Global CNS pure play
- Lead insomnia compound EVT 201
  - Partner-ready, best-in-class
- Broad and deep pipeline, with clinical momentum
  - Proprietary and partnered
- Fully integrated discovery-through-development core competencies
- Multiple partners generating collaborative revenues: Roche, BI, Pfizer, CHDI
- Strong pro-forma cash position of € 141 m*; Nasdaq liquidity

* Based on end of December 2007 cash, after expected transaction costs.

Tomorrow's Drugs Today™



Your contacts:

Jörn Aldag
President & CEO
P: +49.(0)40.56081-375
joern.aldag@evotec.com

Anne Hennecke
SVP, Investor Relations
P: +49.(0)40.56081-286
anne.hennecke@evotec.com